About: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
Creator	Wang, Jing Lu, Jing Li, Rongrong Zhang, Xuefeng Zhao, Shuli
Source	Medline; PMC
abstract	BACKGROUND: A new promising therapeutic approach has emerged for patients chronically infected by the hepatitis B virus (HBV) with the development of a non-replicative adenovirus vector vaccine candidate (Ad-HBV). The vaccine encodes a fusion protein composed of a truncated HBV core protein, mutated polymerase protein, and two envelope domains. In this study, we assessed the immunogenicity of Ad-HBV administered to cynomolgus monkeys during a non-clinical safety assessment. METHODS: The virus was subcutaneously administered at 1.0 × 10(9) viral particles (VP)/animal (low-dose group), 1.0 × 10(10) VP/animal (mid-dose group), and 1.0 × 10(11) VP/animal (high-dose group); the control groups were administered an Ad5-null virus (1.0 × 10(11) VP/animal) and saline only. RESULTS: Except for inflammatory cell infiltration under the skin at the injection sites and transient elevation of body temperature and serum albumin, no Ad-HBV-related toxic effects were noted in any treatment group. Moreover, interferon (IFN)-γ enzyme-linked immunospot assays showed that Ad-HBV induced the targeting of T cells to a broad spectrum of HBV-specific epitopes spanning all three of the selected HBV immunogens (core, polymerase, and envelope domains) in a dose-dependent manner. Although anti-Ad antibody was produced in all groups (except for the saline control), the antibody titers were significantly lower in the high-dose Ad-HBV group than in the group that received the same dose of the Ad-null empty vector. In addition, the IFN-γ and IL-2 expression levels in the liver were significantly improved for the mid-dose, high-dose, and Ad-null control group (p < 0.05), but not for the low-dose group. CONCLUSIONS: Taken together, this safety assessment indicates that the Ad-HBV candidate vaccine is a potent specific immunotherapeutic agent, supporting its further clinical development as an anti-HBV infection vaccine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-1026-3) contains supplementary material, which is available to authorized users.
has issue date	2018-07-24(xsd:dateTime)
bibo:doi	10.1186/s12985-018-1026-3
bibo:pmid	30041659
has license	cc-by
sha1sum (hex)	03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7
schema:url	https://doi.org/10.1186/s12985-018-1026-3
resource representing a document's title	Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
has PubMed Central identifier	PMC6056916
has PubMed identifier	30041659
schema:publication	Virol J
resource representing a document's body	covid:03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7#body_text
is schema:about of	named entity 'HBV' named entity 'GROUP' named entity 'AD5' named entity 'TRUNCATED' named entity 'MUTATED' named entity 'POLYMERASE' named entity 'SALINE' named entity 'CYNOMOLGUS MONKEYS' named entity 'FUSION PROTEIN' named entity 'VECTOR VACCINE' named entity 'SAFETY' named entity 'THERAPEUTIC' named entity 'PROTEIN' named entity 'PROTEIN ' named entity 'CORE PROTEIN' named entity 'PATIENTS' named entity 'VIRAL PARTICLES' named entity 'HEPATITIS B VIRUS' named entity 'CLINICAL' named entity 'BACKGROUND' named entity 'CHRONICALLY' named entity 'VIRUS' named entity 'ASSESSMENT' named entity 'ASSESSMENT' named entity 'VECTOR VACCINE' named entity 'ADMINISTERED' named entity 'DEVELOPMENT' covid:arg/03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7 named entity 'ADENOVIRUS VECTOR' named entity 'ASSESSED' named entity 'COMPOSED OF' named entity 'VACCINE CANDIDATE' named entity 'NEW' named entity 'NON-' named entity 'CLINICAL' named entity 'HEPATITIS B VIRUS' named entity 'SAFETY' named entity 'ADENOVIRUS' named entity 'TARGETING' named entity 'IMMUNOGENICITY' named entity 'IMMUNOGENICITY' named entity 'DOSE' named entity 'APPROACH' named entity 'STUDY' named entity 'INFECTED' named entity 'ENVELOPE' named entity 'METHODS' named entity 'NON-' named entity 'PRIMATES' named entity 'CONTROL GROUPS' named entity 'VACCINE' named entity 'NULL' named entity 'animal' named entity 'animal' named entity 'development' named entity 'hepatitis B virus' named entity 'Ad5' named entity 'low-dose' named entity 'cynomolgus monkeys' named entity 'protein' named entity 'non-human primates' named entity 'non-clinical' named entity 'safety assessment' named entity 'adenovirus' named entity 'clinical development' named entity 'p<0.05' named entity 'antiviral drugs' named entity 'non-clinical' named entity 'infection' named entity 'lung cancer' named entity 'Pol' named entity 'antiviral agents' named entity 'DMEM' named entity 'A549' named entity 'Virus quantification' named entity 'cynomolgus monkeys' named entity 'HLA-A2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software